Arbutamine |
|
| ATC code | |
|---|
|
4-[(1R)-1-hydroxy-2-{[4-(4-hydroxyphenyl)butyl]amino}ethyl]benzene-1,2-diol
|
| CAS Number | |
|---|
| PubChem CID | |
|---|
| DrugBank | |
|---|
| ChemSpider | |
|---|
| UNII | |
|---|
| ChEBI | |
|---|
| ChEMBL | |
|---|
| CompTox Dashboard (EPA) | |
|---|
|
| Formula | C18H23NO4 |
|---|
| Molar mass | 317.385 g·mol−1 |
|---|
| 3D model (JSmol) | |
|---|
Oc1ccc(cc1O)[C@@H](O)CNCCCCc2ccc(O)cc2
|
InChI=1S/C18H23NO4/c20-15-7-4-13(5-8-15)3-1-2-10-19-12-18(23)14-6-9-16(21)17(22)11-14/h4-9,11,18-23H,1-3,10,12H2/t18-/m0/s1 YKey:IIRWWTKISYTTBL-SFHVURJKSA-N Y
|
N Y (what is this?) (verify) |
Arbutamine is a cardiac stimulant. It stimulates β adrenergic receptors.[1]
References
- ^ Abou-Mohamed G, Nagarajan R, Ibrahim TM, Caldwell RW (March 1996). "Characterization of the adrenergic activity of arbutamine, a novel agent for pharmacological stress testing". Cardiovascular Drugs and Therapy. 10 (1): 39–47. doi:10.1007/BF00051129. PMID 8723169. S2CID 30315981.
Adrenergic receptor modulators |
|---|
| α1 | | Agonists | |
|---|
| Antagonists |
- Abanoquil
- ADRIANA
- Ajmalicine
- Alfuzosin
- Anisodamine
- Anisodine
- Atiprosin
- Atypical antipsychotics (e.g., brexpiprazole, clozapine, olanzapine, quetiapine, risperidone)
- Benoxathian
- Beta blockers (e.g., adimolol, amosulalol, arotinolol, carvedilol, eugenodilol, labetalol)
- Buflomedil
- Bunazosin
- Butanserin
- Corynanthine
- Dapiprazole
- Domesticine
- Doxazosin
- Ergolines (e.g., acetergamine, ergotamine, dihydroergotamine, lisuride, nicergoline, terguride)
- Etoperidone
- Fenspiride
- Hydroxyzine
- Indoramin
- Ketanserin
- L-765,314
- mCPP
- Mepiprazole
- Metazosin
- Monatepil
- Moxisylyte
- MT-1207
- Naftopidil
- Nantenine
- Neldazosin
- Niaprazine
- Niguldipine
- Pardoprunox
- Pelanserin
- Perlapine
- Phendioxan
- Phenoxybenzamine
- Phentolamine
- Phenylpiperazine antidepressants (e.g., hydroxynefazodone, nefazodone, trazodone, triazoledione)
- Piperoxan
- Prazosin
- Quinazosin
- Quinidine
- Silodosin
- Spegatrine
- Spiperone
- Talipexole
- Tamsulosin
- Terazosin
- Tiodazosin
- Tolazoline
- Tetracyclic antidepressants (e.g., amoxapine, maprotiline, mianserin)
- Tricyclic antidepressants (e.g., amitriptyline, clomipramine, doxepin, imipramine, trimipramine)
- Trimazosin
- Typical antipsychotics (e.g., chlorpromazine, fluphenazine, loxapine, thioridazine)
- Urapidil
- WB-4101
- Zolertine
|
|---|
|
|---|
| α2 | | Agonists | |
|---|
| Antagonists |
- 1-PP
- Adimolol
- Amesergide
- Aptazapine
- Atipamezole
- Atypical antipsychotics (e.g., asenapine, brexpiprazole, clozapine, lurasidone, olanzapine, paliperidone, quetiapine, risperidone, zotepine)
- Azapirones (e.g., buspirone, gepirone, ipsapirone, tandospirone)
- BRL-44408
- Buflomedil
- Cirazoline
- Efaroxan
- Esmirtazapine
- Fenmetozole
- Fipamezole
- Fluparoxan
- Idazoxan
- Ketanserin
- Lisuride
- mCPP
- Mianserin
- Mirtazapine
- NAN-190
- Pardoprunox
- Phentolamine
- Phenoxybenzamine
- Piperoxan
- Piribedil
- Rauwolscine
- Rotigotine
- Setiptiline
- Spegatrine
- Spiroxatrine
- Sunepitron
- Terguride
- Tolazoline
- Typical antipsychotics (e.g., chlorpromazine, fluphenazine, loxapine, thioridazine)
- Yohimbine
|
|---|
|
|---|
| β | |
|---|
- See also: Receptor/signaling modulators
- Dopaminergics
- Serotonergics
- Monoamine reuptake inhibitors
- Monoamine releasing agents
- Monoamine metabolism modulators
- Monoamine neurotoxins
|
Cardiac stimulants excluding cardiac glycosides (C01C) |
|---|
Adrenergic and dopaminergic agents | | Adrenergic agonists | |
|---|
| Dopamine agonists | |
|---|
| Both | |
|---|
| Unknown/ungrouped | |
|---|
|
|---|
| Phosphodiesterase inhibitors (PDE3I) | |
|---|
| Other cardiac stimulants |
- Angiotensinamide
- Levosimendan
- Omecamtiv mecarbil
- Pimobendan
- Xamoterol
|
|---|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
|